The aim of this project is to develop and subsequently implement on the Polish market and selected European markets (France, Greece, Italy and Germany), a medicinal product with minoxidil, in the form of scalp foam not available to Polish patients. This product will be dedicated to people suffering from androgen alopecia. This type of condition is the most common cause of hair loss in both sexes, the frequency and severity of which increases with age. According to the latest research, androgen alopecia affects nearly 3 in 10 Caucasian women over 30 years of age to almost double the prevalence of women aged 80 and over (57 % of them). Among men, this ailment usually occurs in the third and fourth decades of life and affects between 30 % and 50 % of men aged 50 and about 80 % of white men over 70 years of age. [1] On the Polish market of minoxidil there are no products in the form of foam for the scalp. Almost all preparations containing minoxidil are sold in the form of skin fluids, and only Alocutan is available as a spray. In addition, there is no product on the market containing minoxidil at a concentration of 5 %, which could be used simultaneously by men and women. Available pharmaceuticals of this dose are for male use only. The goal will be achieved as a result of the implementation of 4 stages of R & D work. In Stage 1, formulae and ex-vivo penetration studies will be carried out. In the next Stage, at least one of the selected formulations will be tested for in vitro skin irritation and an in vivo sensitisation potential test. Stage 3 plans to transfer technology and analytical methods to the CMO facility. Contract Manufacturing Organisation) with simultaneous scaling up to target scale and production of GMP registration series. In the last Stage, studies on the stability of the product will be carried out